Alpha Thalassemia (HBA1 and HBA2) Deletion/Duplication with reflex to Hb Constant Spring
Preferred first-tier genetic test for confirmation of suspected alpha thalassemia or alpha thalassemia trait. Use to detect common as well as rare and novel deletions or duplications of the alpha globin gene cluster and the hemoglobin Constant Spring (HbCS) variant.
Multiplex Ligation-dependent Probe Amplification with Sanger sequencing confirmation of HbCS
10-14 days; 21 days if reflexed
New York DOH Approval Status
Lavender (EDTA), pink (K2EDTA), or Yellow (ACD Solution A or B).
Transport 2 mL whole blood. (Min: 1 mL)
Room Temperature: 7 days; Refrigerated: 1 month
Background Information: Alpha Globin (HBA1 and HBA2) Deletion/Duplication
Characteristics: Decreased or absent synthesis of the hemoglobin (Hb) alpha-chain resulting in clinical presentations ranging from asymptomatic silent carriers to severe anemia and fetal lethality. Alpha thalassemia silent carrier commonly results from deletion of a single alpha globin gene (-a/aa) and is clinically asymptomatic. Alpha thalassemia trait may be caused by deletion of a single alpha globin gene from both chromosomes (-a/-a), or deletion of the HBA1 and HBA2 globin genes from the same chromosome (--/aa). Heterozygosity for Hb Constant Spring (HbCS) is usually asymptomatic but may be associated with mild microcytic anemia. Homozygous HbCS is characterized by overt hemolytic anemia, jaundice and splenomegaly. Hemoglobin H disease occurs due to inactivation of three alpha globin genes and results in hemolysis with Heinz bodies, moderate anemia, and splenomegaly. Hb Bart hydrops fetalis syndrome results from deletion of all four alpha globin genes (--/--) and is lethal in the fetal or early neonatal period. Alpha globin gene duplication results in three or more active alpha globin genes on a single chromosome.
Epidemiology: Carrier frequency of alpha thalassemia in African, African-American (1:3), Mediterranean (1:30-50), Middle Eastern, Southeast Asian (1:20).
Inheritance: Autosomal recessive.
Cause: Pathogenic variants in the alpha globin gene cluster (HBZ, HBM, HBA2, HBA1, HBQ1) or regulatory region.
Clinical Sensitivity: Varies by ethnicity, at least 90 percent.
Methodology: Multiplex ligation-dependent probe amplification (MLPA) for the HBZ, HBM, HBA2, HBA1, and HBQ1 genes, the HS-40 regulatory region, and Hb Constant Spring (HbCS) HBA2 c.427T>C; p.Ter143Gln. To determine copy number of HbCS in absence of a concurrent deletion of HBA2, PCR and bidirectional sequencing for HbCS is performed.
Analytical Sensitivity and Specificity: 99 percent.
Limitations: Diagnostic errors can occur due to rare sequence variations. Specific breakpoints of large deletions/duplications will not be determined; therefore, it may not be possible to distinguish variants of similar size. Non-deletional variants within the coding or regulatory regions of the alpha globin cluster genes, other than HbCS, will not be targeted. Individuals carrying both a deletion and duplication within the alpha globin gene cluster may appear to have a normal number of alpha globin gene copies. Rare syndromic or acquired forms of alpha thalassemia associated with ATRX gene variants will not be detected.
This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.
Counseling and informed consent are recommended for genetic testing. Consent forms are available online.
Laboratory Developed Test (LDT)
If a concurrent deletion of HBA2 is not identified, PCR and bidirectional sequencing for the HbCS copy number will be performed. Additional charges apply.
81269; if reflexed, add 81257
|Component Test Code*||Component Chart Name||LOINC|
|3003657||HBA DDCS Interpretation|
- A globin
- Alpha globin gene analysis
- Alpha globin mutations
- Alpha thalassemia